Ligand Pharma CFO Sells Shares Amid 80% Share Price Surge

Ligand Pharmaceuticals CFO Octavio Espinoza sold 3,057 shares of common stock for $688,000, reducing his direct ownership from 24,067 to 21,010 shares. The sale was executed directly, with no indirect or trust entities involved, and represents 12.70% of his direct common stock holdings. The transaction value exceeded the March 11, 2026 closing and opening market prices, suggesting favorable pricing was captured.